Rubius, after layoffs and executive turnover, sets plan to dissolve
WEBFeb 22, 2023 · Rubius Therapeutics on Wednesday revealed plans to shut down and liquidate its assets, four years after it went public at a nearly $2 billion valuation with the goal to re-engineer blood cells to fight disease.
Rubius Therapeutics Outlines Dissolution Plan, After Unsuccessful ...
WEBFeb 22, 2023 · In September, Rubius Therapeutics announced plans to restructure and align resources to advance its next-generation red blood cell-based cell conjugation platform. It discontinued Phase 1 trials...
Rubius Therapeutics to shut down. It's a lesson for biotech - STAT
WEBFeb 22, 2023 · On Wednesday, the company — battered down to a market value of $15 million — said it was shutting down and liquidating all of its remaining assets. The official end of Rubius marks one of ...
Rubius moves to dissolve after last-ditch effort - Fierce Biotech
WEBFeb 22, 2023 · After a last-ditch effort last year to try to refocus, the Cambridge, Massachusetts-based company will now liquidate and dissolve. Rubius announced the news in a Securities and Exchange...
Rubius Therapeutics Announces Strategic Update - GlobeNewswire
WEBSep 13, 2022 · Company to Focus on Advancing Next Generation Red Blood Cell-Based Cell Conjugation Platform. Initiating Cost-Saving Measures Through Corporate Restructuring; Cash Runway Extended to End of 2023 ...
Rubius, a once high-flying biotech startup, lays off much of its staff
WEBSep 13, 2022 · Rubius Therapeutics, a biotechnology company aiming to turn engineered blood cells into medicines, will lay off 75% of its staff and stop development of its two most advanced drug prospects.
Rubius Therapeutics Announces Process to Explore Strategic …
WEBNov 2, 2022 · Rubius is employing cell conjugation to generate therapeutic red blood cells with two distinct modalities – potent cell-cell interaction and tolerance induction.
Rubius Therapeutics Announces Process to Explore Strategic
WEBNov 2, 2022 · Rubius is employing cell conjugation to generate therapeutic red blood cells with two distinct modalities – potent cell-cell interaction and tolerance induction.
Rubius scraps lead candidate as it exits rare disease drugmaking
WEBMar 12, 2020 · Rubius Therapeutics will end development of its most advanced drug as the Cambridge, Massachusetts-based biotech looks to save money by moving away from rare disease research.
Rubius Therapeutics Announces Dosing of First Patient in
WEBJan 13, 2022 · Rubius Therapeutics, Inc. today announced that the first patient has been dosed in its Phase 1/2 clinical trial of RTX-224 for the treatment of patients with certain relapsed/refractory or locally advanced solid tumors. ... BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to ...